EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

Sattva S Neelapu iD, Caron A Jacobson, Armin Ghobadi iD, David B Miklos iD, Lazaros J Lekakis, Olalekan O Oluwole iD, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abhinav Deol iD, Patrick M Reagan und 18 weitere

Blood · 23.02.2023

DOI: 10.1182/blood.2022018893 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Blood, online erschienen am 23.02.2023. Verfasst von Sattva S Neelapu und 29 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Biological Products, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 152-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In phase 2 of ZUMA-1, a single-arm, multicenter, registrational trial, axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy demonstrated durable responses at 2 years in patients with refractory large B-cell lymphoma (LBCL). Here, we aimed to assess survival and safety in ZUMA-1 after 5 years of follow-up. Eligible adults with refractory LBCL (diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, and transformed follicular lymphoma) received lymphodepleting chemotherapy followed by axi-cel infusion targeted at 2×106 cells/kg. Investigator-assessed response, updated survival, safety, and pharmacokinetic outcomes were assessed in treated patients. The objective response rate in the 101 treated patients was 83% (58% complete response rate), and with a median follow-up of 63.1 months, responses were ongoing at data cutoff in 31%. Median overall survival (OS) was 25.8 months and the estimated 5-year OS rate was 42.6%. Disease-specific survival (excluding deaths unrelated to disease progression) estimated at 5 years was 51.0%. No new serious adverse events or deaths related to axi-cel were observed after additional follow-up. Peripheral blood B cells were detectable in all evaluable patients at 3 years with polyclonal B-cell recovery in 91%. Ongoing responses at 60 months were associated with early CAR T-cell expansion. In conclusion, this 5-year follow-up analysis of ZUMA-1 demonstrates sustained overall and disease-specific survival, with no new safety signals in patients with refractory LBCL. Protracted B-cell aplasia was not required for durable responses. These findings support the curative potential of axi-cel in a subset of patients with aggressive B-cell lymphomas. ClinicalTrials.gov, number NCT02348216

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseBiological ProductsReceptors, Chimeric AntigenAdultHumansFollow-Up StudiesImmunotherapy, AdoptiveAntigens, CD19

Substanzen

axicabtagene ciloleucelBiological ProductsReceptors, Chimeric AntigenAntigens, CD19

Autor:innen und Institutionen

  • Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Division of Medical Oncology, Washington University School of Medicine, St Louis, MO.
  • Department of Medicine-Med/Blood and Marrow Transplantation, Stanford University School of Medicine, Stanford, CA.
  • Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL.
  • Vanderbilt-Ingram Cancer Center, Nashville, TN.

ORCID-Profile: Sattva S Neelapu, Armin Ghobadi, David B Miklos, Olalekan O Oluwole, Abhinav Deol, Patrick Stiff, Ian W Flinn, Umar Farooq, Andre H Goy, Javier Munoz, Alex F Herrera

Förderung

  • NCI NIH HHS

Zitieren

APA

Neelapu, S. S., Jacobson, C. A., Ghobadi, A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P., Flinn, I. W., Farooq, U., Goy, A. H., McSweeney, P. A., Munoz, J., Siddiqi, T., …, & Locke, F. L. (2023). 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. https://doi.org/10.1182/blood.2022018893

Vancouver

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1). Blood. 2023. doi:10.1182/blood.2022018893

BibTeX
@article{Neelapu2023,
  author = {Neelapu, Sattva S and Jacobson, Caron A and Ghobadi, Armin and Miklos, David B and Lekakis, Lazaros J and Oluwole, Olalekan O and Lin, Yi and Braunschweig, Ira and Hill, Brian T and Timmerman, John M and Deol, Abhinav and Reagan, Patrick M and Stiff, Patrick and Flinn, Ian W and Farooq, Umar and Goy, Andre H and McSweeney, Peter A and Munoz, Javier and Siddiqi, Tanya and Chavez, Julio C and Herrera, Alex F and Bartlett, Nancy L and Bot, Adrian A and Shen, Rhine R and Dong, Jinghui and Singh, Kanwarjit and Miao, Harry and Kim, Jenny J and Zheng, Yan and Locke, Frederick L},
  title = {5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022018893}
}
Kostenlos starten →